Rad51 Degradation: Role in Oncolytic Virus—Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma

Background: Clinical success of poly(ADP-ribose) polymerase inhibitors (PARPi) has been limited to repair-deficient cancers and by resistance. Oncolytic herpes simplex viruses (oHSVs) selectively kill cancer cells, irrespective of mutation, and manipulate DNA damage responses (DDR). Here, we explore...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Natl Cancer Inst
Autors principals: Ning, Jianfang, Wakimoto, Hiroaki, Peters, Cole, Martuza, Robert L., Rabkin, Samuel D.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2017
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6059185/
https://ncbi.nlm.nih.gov/pubmed/28376211
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djw229
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars